Patents Assigned to IRM LLC
  • PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
    Publication number: 20100190811
    Abstract: The invention provides a novel class of pyrimidine derivatives, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR? and PDGFR? kinases.
    Type: Application
    Filed: May 1, 2008
    Publication date: July 29, 2010
    Applicant: IRM LLC
    Inventors: Xiaolin Li, Xiaodong Liu, Valentina Molteni
  • COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
    Publication number: 20100184791
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR? and PDGFR? kinases.
    Type: Application
    Filed: May 2, 2008
    Publication date: July 22, 2010
    Applicant: IRM LLC
    Inventors: Xiaolin Li, Xiaodong Liu, Valentina Molteni
  • COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS
    Publication number: 20100183564
    Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
    Type: Application
    Filed: October 29, 2009
    Publication date: July 22, 2010
    Applicant: IRM LLC
    Inventors: Anthony E. Boitano, Michael Cooke, Shifeng Pan, Peter G. Schultz, John Tellew, Yongqin Wan, Xing Wang
  • COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS
    Publication number: 20100184748
    Abstract: The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
    Type: Application
    Filed: June 12, 2008
    Publication date: July 22, 2010
    Applicant: IRM LLC
    Inventors: Badry Bursulaya, Dai Cheng, Jiqing Jiang, Donald S. Karanewsky, Yi Liu, Shifeng Pan, Yongqin Wan, Xia Wang, Yun Feng Xie, Yang Yang
  • Compounds and compositions as PPAR modulators
    Patent number: 7750032
    Abstract: The invention provides trisubstituted pyrazoles and imidazoles of Formula I: wherein L2, q, R13, R14, R15, R16, Z1 and Z2 are as described in the Summary of the Invention; and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the peroxisome proliferator-activated receptor (PPAR) families, particularly the activity of PPAR?.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: July 6, 2010
    Assignee: IRM LLC
    Inventors: Christopher Cow, Robert Epple, Xing Wang, Yongping Xie, Hans Martin Seidel
  • Immunosuppressant compounds and compositions
    Patent number: 7750021
    Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: July 6, 2010
    Assignee: IRM LLC
    Inventors: Yuan Mi, Shifeng Pan, Nathanael Schiander Gray, Wenqi Gao, Yi Fan, Tao Jiang
  • COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20100168182
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly TrkA, TrkB, TrkC, PDGFR and c-kit.
    Type: Application
    Filed: December 11, 2007
    Publication date: July 1, 2010
    Applicant: IRM LLC
    Inventors: Yuan Mi, Pamela Albaugh, Yi Fan, Ha-Soon Choi, Zuosheng Liu, Shenlin Huang
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 7745437
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ??K, T??2, ???, ?NK2?2, MKK4, c-RAF, MKK6, SAPK2? and SAPK2? kinases.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: June 29, 2010
    Assignee: IRM LLC
    Inventors: Pingda Ren, Xia Wang, Guobao Zhang, Qiang Ding, Shuli You, Qiong Zhang, Greg Chopiuk, Pamela A. Albaugh, Taebo Sim, Nathanael Schiander Gray
  • Compounds and compositions as PPAR modulators
    Patent number: 7745445
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR?.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: June 29, 2010
    Assignee: IRM LLC
    Inventors: Robert Epple, Mihai Azimioara
  • AGONIST TRKB ANTIBODIES AND USES THEREOF
    Publication number: 20100150914
    Abstract: TrkB agonist antibodies and methods of their use are provided.
    Type: Application
    Filed: November 6, 2007
    Publication date: June 17, 2010
    Applicant: IRM LLC
    Inventors: Yan Wang, Steven B. Cohen, Marc Nasoff
  • Inhibitors of cathepsin S
    Patent number: 7732449
    Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. More particularly, the present invention provides compounds having Formula 1: wherein Q is an optionally substituted piperazinyl; and A, R5, R6, R7, R8, R9 and Ar are substituents.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: June 8, 2010
    Assignee: IRM LLC
    Inventors: Hong Liu, Arnab K. Chatterjee, David C. Tully, Phillip B. Alper, David H. Woodmansee
  • Immunosuppressant compounds and compositions
    Patent number: 7718704
    Abstract: The invention provides a novel class of cyclic oximes of Formula I: wherein A, X, Y, Z, W, R1, R2, R3 and n are as described in the summary of the invention; useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: May 18, 2010
    Assignee: IRM LLC
    Inventors: Shifeng Pan, Wenqi Gao, Nathanael Schiander Gray, Yuan Mi
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20100120807
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: March 5, 2008
    Publication date: May 13, 2010
    Applicant: IRM LLC
    Inventors: Phillip B. Alper, Gerald Lelais, Robert Epple, Daniel Mutnick
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 7713958
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases and disorders associated with kinase activity, particularly diseases associated with the activity of CDK1, CDK2, CDK4, CDK5, GSK3?, Bcr-abl, Flt-3, c-Kit, PDGFR?, Src, Mek1 and CK1.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: May 11, 2010
    Assignee: IRM LLC
    Inventors: Yongqin Wan, Nathanael S. Gray
  • PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF
    Publication number: 20100087464
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of TrkA, TrkB, TrkC, Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC?, Raf, ROCK-II, Rsk1, and SGK kinases, or a combination thereof.
    Type: Application
    Filed: August 27, 2007
    Publication date: April 8, 2010
    Applicant: IRM LLC
    Inventors: Yuan Mi, Pamela A. Albaugh
  • COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS
    Publication number: 20100081656
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.
    Type: Application
    Filed: December 2, 2009
    Publication date: April 1, 2010
    Applicant: IRM LLC
    Inventors: Donatella Chianelli, Christopher Cow, Yun He, Songchun Jiang, Xiaolin Li, Xiaodong Liu, Zuosheng Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Pingda Ren, Taebo Sim, Xiaodong Wang, Shuli You
  • Compositions and methods for modulating c-kit and PDGFR receptors
    Patent number: 7678792
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: March 16, 2010
    Assignee: IRM LLC
    Inventors: Donatella Chianelli, Christopher Cow, Yun He, Songchun Jiang, Xiaolin Li, Xiaodong Liu, Zuosheng Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Pingda Ren, Taebo Sim, Xiaodong Wang, Shuli You
  • COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
    Publication number: 20100056756
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Application
    Filed: January 7, 2008
    Publication date: March 4, 2010
    Applicant: IRM LLC
    Inventors: David C. Tully, Arnab K. Chatterjee, Zhiwei Wang
  • PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES
    Publication number: 20100056494
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with kinase activity, particularly malaria.
    Type: Application
    Filed: January 10, 2008
    Publication date: March 4, 2010
    Applicants: IRM LLC, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Elizabeth Winzeler, Nathanael S. Gray, Dong Han, Dai Cheng
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20100048539
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR? and PDGFR? kinases. Formula (I).
    Type: Application
    Filed: November 2, 2007
    Publication date: February 25, 2010
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Donatella Chianelli, Xiaolin Li, Xiaodong Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Laszlo Revesz, Lawrence B. Perez, Clinton Brooks, Wojciech Wrona, Paul William Manley, Werner Breitenstein